NasdaqGS - Nasdaq Real Time Price USD

Regeneron Pharmaceuticals, Inc. (REGN)

973.80 +5.80 (+0.60%)
As of May 10 at 4:00 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
13,100,100.00
13,117,200.00
12,172,900.00
16,071,700.00
8,497,100.00
Cost of Revenue
1,792,100.00
1,815,800.00
1,560,400.00
2,437,500.00
1,119,900.00
Gross Profit
11,308,000.00
11,301,400.00
10,612,500.00
13,634,200.00
7,377,200.00
Operating Expense
7,319,100.00
7,068,200.00
5,618,500.00
4,639,400.00
3,800,600.00
Operating Income
3,988,900.00
4,233,200.00
4,994,000.00
8,994,800.00
3,576,600.00
Net Non Operating Interest Income Expense
491,100.00
422,900.00
100,700.00
-11,500.00
-56,900.00
Other Income Expense
-438,000.00
-456,800.00
-235,900.00
342,500.00
290,700.00
Pretax Income
4,042,000.00
4,199,300.00
4,858,800.00
9,325,800.00
3,810,400.00
Tax Provision
184,200.00
245,700.00
520,400.00
1,250,500.00
297,200.00
Net Income Common Stockholders
3,857,800.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Diluted NI Available to Com Stockholders
3,857,800.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Basic EPS
36.11
37.05
40.51
76.40
32.65
Diluted EPS
33.87
34.77
38.22
71.97
30.52
Basic Average Shares
106,875.00
106,700.00
107,100.00
105,700.00
107,600.00
Diluted Average Shares
113,975.00
113,700.00
113,500.00
112,200.00
115,100.00
Total Operating Income as Reported
3,851,800.00
4,047,100.00
4,738,900.00
8,946,800.00
3,576,600.00
Total Expenses
9,111,200.00
8,884,000.00
7,178,900.00
7,076,900.00
4,920,500.00
Net Income from Continuing & Discontinued Operation
3,857,800.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Normalized Income
4,257,991.87
4,364,628.80
4,556,917.10
7,782,159.00
3,513,200.00
Interest Income
562,200.00
495,900.00
160,100.00
45,800.00
--
Interest Expense
71,100.00
73,000.00
59,400.00
57,300.00
56,900.00
Net Interest Income
491,100.00
422,900.00
100,700.00
-11,500.00
-56,900.00
EBIT
4,113,100.00
4,272,300.00
4,918,200.00
9,383,100.00
3,867,300.00
EBITDA
4,548,700.00
4,693,300.00
5,259,600.00
9,669,300.00
4,103,200.00
Reconciled Cost of Revenue
1,792,100.00
1,815,800.00
1,560,400.00
2,437,500.00
1,119,900.00
Reconciled Depreciation
435,600.00
421,000.00
341,400.00
286,200.00
235,900.00
Net Income from Continuing Operation Net Minority Interest
3,857,800.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Total Unusual Items Excluding Goodwill
-419,300.00
-436,800.00
-244,700.00
338,500.00
--
Total Unusual Items
-419,300.00
-436,800.00
-244,700.00
338,500.00
--
Normalized EBITDA
4,968,000.00
5,130,100.00
5,504,300.00
9,330,800.00
4,103,200.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-19,108.13
-25,771.20
-26,182.90
45,359.00
--
12/31/2020 - 4/2/1991

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VRTX Vertex Pharmaceuticals Incorporated
425.99
+0.76%
 
CRSP CRISPR Therapeutics AG
51.17
-4.44%
 
NTLA Intellia Therapeutics, Inc.
24.46
-1.61%
 
MDGL Madrigal Pharmaceuticals, Inc.
205.25
-0.81%
 
BNTX BioNTech SE
92.56
+0.97%
 
SRPT Sarepta Therapeutics, Inc.
131.82
-0.36%
 
ALNY Alnylam Pharmaceuticals, Inc.
151.28
+0.54%
 
BMRN BioMarin Pharmaceutical Inc.
81.03
-0.84%
 
MRNA Moderna, Inc.
117.31
-4.39%
 
VKTX Viking Therapeutics, Inc.
73.64
-8.18%